Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
Status: | Completed |
---|---|
Conditions: | Cancer, Cancer, Other Indications, Blood Cancer, Endocrine, Leukemia |
Therapuetic Areas: | Endocrinology, Oncology, Other |
Healthy: | No |
Age Range: | 1 - 20 |
Updated: | 4/22/2017 |
Start Date: | November 2008 |
End Date: | April 2016 |
The Metabolic Syndrome in Pediatric Acute Lymphoblastic Leukemia (ALL).
RATIONALE: Gathering information about metabolic syndrome from young patients with acute
lymphoblastic leukemia may help doctors learn more about the disease.
PURPOSE: This phase I trial is studying the metabolic syndrome in young patients with acute
lymphoblastic leukemia in remission.
lymphoblastic leukemia may help doctors learn more about the disease.
PURPOSE: This phase I trial is studying the metabolic syndrome in young patients with acute
lymphoblastic leukemia in remission.
OBJECTIVES:
Primary
- To determine the incidence and prevalence of the components of metabolic syndrome
(e.g., obesity, hypertension, dyslipidemia, and insulin resistance) in pediatric
patients with acute lymphoblastic leukemia in remission.
- To determine the trajectory of the onset of these components over a 1-year period in
patients undergoing maintenance therapy.
Secondary
- To identify potential associations between components of metabolic syndrome and
fatigue, health-related quality of life, family history, nutrition, and physical
activity.
- To identify potential biomarkers that are associated with clinical features of
metabolic syndrome.
- To evaluate whether patients will show a decrease in IGF-1 levels.
OUTLINE: This is a two-part study. Patients are enrolled in either part 1 or part 2.
- Part 1: Patients undergo physical exam measurements (e.g., body mass index, waist
circumference, and blood pressure) at baseline (during maintenance course 1) and at 12
months (during maintenance course 5). Patients also undergo blood sample collection at
baseline and at 12 months to measure laboratory markers (e.g., fasting lipid profile,
fasting insulin and glucose, IGF-1, leptin, and adiponectin levels). Patients or their
parents complete a family history questionnaire at baseline and questionnaires to
assess physical activity, quality of life, nutritional intake, and fatigue at baseline
and at 6 and 12 months.
- Part 2: Patients or their parents complete a family history questionnaire at baseline.
Primary
- To determine the incidence and prevalence of the components of metabolic syndrome
(e.g., obesity, hypertension, dyslipidemia, and insulin resistance) in pediatric
patients with acute lymphoblastic leukemia in remission.
- To determine the trajectory of the onset of these components over a 1-year period in
patients undergoing maintenance therapy.
Secondary
- To identify potential associations between components of metabolic syndrome and
fatigue, health-related quality of life, family history, nutrition, and physical
activity.
- To identify potential biomarkers that are associated with clinical features of
metabolic syndrome.
- To evaluate whether patients will show a decrease in IGF-1 levels.
OUTLINE: This is a two-part study. Patients are enrolled in either part 1 or part 2.
- Part 1: Patients undergo physical exam measurements (e.g., body mass index, waist
circumference, and blood pressure) at baseline (during maintenance course 1) and at 12
months (during maintenance course 5). Patients also undergo blood sample collection at
baseline and at 12 months to measure laboratory markers (e.g., fasting lipid profile,
fasting insulin and glucose, IGF-1, leptin, and adiponectin levels). Patients or their
parents complete a family history questionnaire at baseline and questionnaires to
assess physical activity, quality of life, nutritional intake, and fatigue at baseline
and at 6 and 12 months.
- Part 2: Patients or their parents complete a family history questionnaire at baseline.
DISEASE CHARACTERISTICS:
Part 1
- Diagnosis of precursor B-cell acute lymphoblastic leukemia (ALL)
- In first remission
- In first 3 months of maintenance therapy
- No T-cell ALL, very high-risk ALL, or infant ALL (< 1 year old at diagnosis)
Part 2
- Diagnosis of precursor B-cell or T-cell ALL
- In first remission
- Must have been diagnosed and treated (at least to the maintenance phase) at the
Division of Pediatric Oncology at the Vanderbilt-Ingram Cancer Center within the past
7 years
- No very high-risk ALL or infant ALL (< 1 year old at diagnosis)
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior or concurrent cranial radiotherapy (Part 1)
We found this trial at
3
sites
324 Cool Springs Blvd
Nashville, Tennessee 37067
Nashville, Tennessee 37067
(877) 936-8422
Vanderbilt-Ingram Cancer Center - Cool Springs Vanderbilt-Ingram Cancer Center Cool Springs is a medical oncology...
Click here to add this to my saved trials
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials
2107 Edward Curd Lane
Nashville, Tennessee 37067
Nashville, Tennessee 37067
615-591-9890
Vanderbilt-Ingram Cancer Center at Franklin The Vanderbilt-Ingram Cancer Center at Franklin is a free-standing radiation...
Click here to add this to my saved trials